Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009




Bortezomib Relapsed vs.
       Refractory               Median PFS*             Median OS**
-----------------------         -----------             -----------

                                                     Not Reached at 38+
Bortezomib Relapsed (n=20)       8.8 months                months
--------------------------       ----------          ------------------
                              95% CI (6.3, 11.2)      95% CI (25, NR)
                              ------------------      ---------------


Bortezomib Refractory (n=53)     5.7 months             22.5 months
                                 ----------             -----------
                              95% CI (4.3, 6.4)       95% CI (12.3, NR)
----------------------------  -----------------       -----------------


*  Median PFS and median TTP were identical, as no patient deaths
   occurred prior to progression.
** Kaplan Meier methodology was used to determine overall survival
   figures.

No unexpected adverse events have been observed. Toxicities were manageable with supportive care.

Commenting on the data, Dr. Paul Richardson stated, "Perifosine continues to demonstrate an impressive response rate and extended progression-free survival when combined with bortezomib and dexamethasone in a heavily pre-treated patient population. The new survival data reported is particularly encouraging with a median overall survival of more than 2 years. We look forward to pursuing this combination in the randomized Phase 3 trial."

Dr. Kenneth Anderson, Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, added, "The data presented here further supports the planned Phase 3 trial design which has been granted Special Protocol Assessment by the FDA. We are excited to be launching the multi-center trial for this very promising agent."

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We wish to thank the im
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... More than a third of reproductive-aged women enrolled in Medicaid, ... filled a prescription for an opioid pain medication each year ... and Mortality Weekly Report (MMWR). Opioids are ... severe pain.  They are also found in some prescription cough ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
...  Paragon Bioservices, Inc., a Baltimore-based CMO focused on ... today that it has been awarded a JVAP-CBMS ... the vaccine development and subsequent GMP manufacturing of ... The initial phase of the contract is ...
... Jan. 17, 2012 Roka Bioscience announced today that ... Performance Tested Method(SM) certification from the AOAC Research ... by Silliker, Inc., as part of the AOAC-RI independent ... Roka Listeria Detection Assay runs on the Atlas™ System, ...
Cached Medicine Technology:Paragon Bioservices Awarded Multi-Million Dollar DoD Contract for Filovirus Vaccine Development and Manufacturing 2Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay 2
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... TN (PRWEB) January 22, 2015 Gabe’s Chemo Duck ... Duck App, the first app ever created for kids with cancer. ... Apple phones and devices, is filled with enjoyable games to help ... and treatments. The free app helps to keep kids entertained, educated ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Labors preventative health care plan as a timely and ... ,Dr Capolingua said the policy recognises that ... disease in the community, including among younger people, will ... medical workforce in the years and decades ahead. ...
... one week in Adelaide from Sunday 1 July for ... Students Association (AMSA). ,The largest medical student ... students from each of Australias 17 medical schools together ... activities. ,The Convention will feature keynote speakers ...
... cause more deaths in summer because of higher temperatures but ... winters finds an analysis published online ahead of print ... analysed city-specific weather data related to the deaths of more ... and 2000. ,They found that during two-day cold ...
... US researchers are conducting a study to understand the ... they are using the bacterial pathogen Listeria Monocytogenes ... includes University of Central Florida Microbiology Professor Keith Ireton, ... induces internalisation and degradation of a human receptor known ...
... of Cincinnati has resulted in the Advisers to the ... that all teens between the ages of 11 and ... ,The guidelines are especially aimed at protecting ... bacterial meningitis, the CDC said. Adolescents and young adults ...
... Zealand researchers took measurements of lung capacity and inflammation ... To measure inflammation, they looked at the amount ... the blood. Higher levels of CRP were found in ... ,Although increased levels of markers for inflammation have ...
Cached Medicine News:Health News:Labor's Preventive Health Care Policy Looks to Address Future Needs 2Health News:Death Rates Will Rise Because of Global Warming 2Health News:Study of Bacterial Pathogen may Give Insight to Cancer Development 2Health News:Meningitis Shots for Teens 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
Qualitative EIA for SS-A, SS-B, Sm, Sm/RNP plus Scl-70 and Jo-1...
Enzyme-linked immunosorbent assays for the detection and quantitation of IgG antibodies to extractable nuclear antigens (ENA) Sm in human serum.Antibodies to Sm aid in the diagnosis of systemic lupus...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... serum. Antibodies to Sm aid ... lupus erythematosus (SLE). ,RNP antibodies ...
Medicine Products: